Clinical Trial Update: Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial of vorinostat, erlotinib, and temozolomide in recurrent glioblastoma multiforme (GBM) was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Cancer
• Glioblastoma Multiforme

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Temozolomide (Temozolomide)
• Vorinostat (vorinostat)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Brain Cancer, Glioblastoma Multiforme | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-08-25